- Home
- OKYO vs CYTH Comparison
OKYO vs CYTH Comparison
Compare OKYO & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- CYTH
- Stock Information
- Founded
- OKYO 2007
- CYTH 1990
- Country
- OKYO United Kingdom
- CYTH United States
- Employees
- OKYO N/A
- CYTH N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- CYTH Health Care
- Exchange
- OKYO Nasdaq
- CYTH Nasdaq
- Market Cap
- OKYO 37.0M
- CYTH 31.9M
- IPO Year
- OKYO 2022
- CYTH N/A
- Fundamental
- Price
- OKYO $1.12
- CYTH $0.91
- Analyst Decision
- OKYO Strong Buy
- CYTH Buy
- Analyst Count
- OKYO 1
- CYTH 3
- Target Price
- OKYO $7.00
- CYTH $0.95
- AVG Volume (30 Days)
- OKYO 273.5K
- CYTH 4.5M
- Earning Date
- OKYO 03-04-2025
- CYTH 03-17-2025
- Dividend Yield
- OKYO N/A
- CYTH N/A
- EPS Growth
- OKYO N/A
- CYTH N/A
- EPS
- OKYO N/A
- CYTH N/A
- Revenue
- OKYO N/A
- CYTH $870,725.00
- Revenue This Year
- OKYO N/A
- CYTH N/A
- Revenue Next Year
- OKYO N/A
- CYTH $24.49
- P/E Ratio
- OKYO N/A
- CYTH N/A
- Revenue Growth
- OKYO N/A
- CYTH N/A
- 52 Week Low
- OKYO $0.81
- CYTH $0.55
- 52 Week High
- OKYO $1.90
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- OKYO 54.76
- CYTH 53.59
- Support Level
- OKYO $1.01
- CYTH $0.85
- Resistance Level
- OKYO $1.13
- CYTH $1.45
- Average True Range (ATR)
- OKYO 0.06
- CYTH 0.13
- MACD
- OKYO 0.00
- CYTH -0.00
- Stochastic Oscillator
- OKYO 61.76
- CYTH 22.83
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.